drugset / Trial / NCT04280328
Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1b open-label study of ciforadenant, an oral, small molecule inhibitor targeting adenosine-2A receptors (A2AR), on safety/tolerability and efficacy in combination with daratumumab, a monoclonal antibody targeting CD38, in relapsed or refractory multiple myeloma.
Timeline
- Start
- 2020-02-20
- Primary completion
- 2021-09-21
- Completion
- 2022-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ciforadenant | Small molecule | 100 mg | Oral |
| Background | Daratumumab | Monoclonal antibody | 16 mg/kg | Intravenous |